Ravicti
Generic name: Glycerol Phenylbutyrate
Drug class:
Urea cycle disorder agents
Usage of Ravicti
Ravicti binds with other substances in the liver and kidneys to help eliminate nitrogen from the body. Excess nitrogen can cause hyperammonemi, a build-up of ammonia in the blood. Ammonia is very toxic when it circulates in blood and tissues and can cause permanent brain damage, coma, or death.
Ravicti helps prevent a build-up of ammonia in the blood in adults and children with Urea cycle disorder. This medicine will not treat hyperammonemia.
Ravicti is usually given together with a low-protein diet and sometimes dietary supplements.
Ravicti side effects
Get emergency medical help if you have signs of an allergic Reaction to Ravicti: hives; cough, wheezing, difficult breathing; feeling like you might pass out; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any signs of high blood levels of ammonia (hyperammonemia):
Ravicti can affect your nervous system. Call your doctor at once if you have:
Common Ravicti side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Ravicti
You should not use Ravicti if you are allergic to glycerol phenylbutyrate.
To make sure Ravicti is safe for you, tell your doctor if you have ever had:
It is not known whether glycerol phenylbutyrate will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
If you become pregnant, your name may be listed on a pregnancy registry. This is to track the outcome of the pregnancy and to evaluate any effects of glycerol phenylbutyrate on the baby.
You should not breastfeed while using Ravicti.
Relate drugs
How to use Ravicti
Usual Adult Dose of Ravicti for Urea Cycle Disorders:
Initial Doses: Administer orally in 3 equally divided dosages rounded up to the nearest 0.5 mL: -Phenylbutyrate-Naive Patients: 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) -Phenylbutyrate-Naive Patients with Some Residual Enzyme Activity: 4.5 mL/m2/day -Patients Switching from sodium phenylbutyrate, use the following conversion: --Tablets: Total daily dose of glycerol phenylbutyrate (mL)=total daily dose of sodium phenylbutyrate tablets (g) x 0.86 --Powder: Total daily dose of glycerol phenylbutyrate (mL)=total daily dose of sodium phenylbutyrate powder (g) x 0.81 MAINTENANCE DOSES: Follow clinically and with plasma ammonia levels, especially with changing doses; for elevated plasma ammonia, increase dose to maintain fasting plasma ammonia to less than half the upper limit of normal; if the phenylacetate (PAA) to phenylacetylglutamine (PAGN) ratio and urinary phenylacetylglutamine (U-PAGN) measurement are available, this will help guide dosing; product labeling may be consulted for additional information MAXIMUM DOSE: 17.5 mL (19 g) per day
Usual Pediatric Dose of Ravicti for Urea Cycle Disorders:
Initial Doses: -Patients less than 2 years: Administer in 3 or more equally divided dosages, rounded up to the nearest 0.1 mL -Patients 2 years or older: Administer in 3 equally divided dosages, rounded up to the nearest 0.5 mL Phenylbutyrate-Naive Patients: 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) Phenylbutyrate-Naive Patients with Some Residual Enzyme Activity: 4.5 mL/m2/day Patients Switching from sodium phenylbutyrate, use the following conversion: --Tablets: Total daily dose of glycerol phenylbutyrate (mL)=total daily dose of sodium phenylbutyrate tablets (g) x 0.86 --Powder: Total daily dose of glycerol phenylbutyrate (mL)=total daily dose of sodium phenylbutyrate powder (g) x 0.81 MAINTENANCE DOSES: -Patients 6 years or older: Follow clinically and with plasma ammonia levels, especially with changing doses; for elevated plasma ammonia, increase dose to maintain fasting plasma ammonia to less than half the upper limit of normal; if the phenylacetate (PAA) to phenylacetylglutamine (PAGN) ratio and urinary phenylacetylglutamine (U-PAGN) measurement are available, this will help guide dosing; product labeling may be consulted for additional information -Patients less than 6 years: Follow above guidance, however, if obtaining fasting ammonia is problematic due to frequent feedings, adjust the dose to keep the first ammonia of the morning below the upper limit for age MAXIMUM DOSE: 17.5 mL (19 g) per day Comments: -When determining the starting dose, consider the patient's residual urea synthetic capacity, dietary protein requirements, and diet adherence; may consider an initial estimated daily dose of 0.6 mL per gram of dietary protein ingested per 24-hour period. -Must use with dietary protein restriction and in some cases, with dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). -Not indicated for the treatment of acute hyperammonemia as more rapid interventions should be used. -Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. Use: As a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Warnings
Ravicti can affect your nervous system. Call your doctor right away if you have: confusion, headaches, memory problems, hearing problems, vomiting, an altered sense of taste, numbness or tingling in your hands or feet, or if you feel unusually sleepy or light-headed.
What other drugs will affect Ravicti
Sometimes it is not safe to use certain medications at the SAMe time. Certain other drugs can affect your blood levels of ammonia, making Ravicti less effective or causing hyperammonemia.
Many drugs can interact with glycerol phenylbutyrate. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions